Breaking News Instant updates and real-time market news.

GILD

Gilead

$77.32

0.14 (0.18%)

17:02
08/14/18
08/14
17:02
08/14/18
17:02

Gilead announces management changes and appointments

Gilead Sciences announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company's medicines and increase focus on reaching patients. The company also announced that Diana Brainard has been promoted to Senior Vice President, HIV and Emerging Viral Infections, and that Andrew Cheng Chief Medical Officer, has decided to leave Gilead to pursue another opportunity. Alton joined the company nearly 20 years ago and was the architect of its access program, which has enabled Gilead's HIV medicines to reach more than 11 million people in the developing world. He has helped shape the organization in a number of executive positions, including as general counsel, and more recently, leading the company's international commercial operations and corporate affairs groups. Brainard joined Gilead in 2010. She has extensive training and experience in immunology, infectious diseases and drug development. Under her leadership, Gilead received regulatory approval of four chronic hepatitis C virus therapies in a period of less than four years. She was promoted to Vice President, Clinical Research, Liver Diseases, in 2015. Cheng joined Gilead in 1999 to lead the company's development-stage programs in HIV/AIDS. He received additional responsibility for the company's Development Operations organization in 2009 and was named Executive Vice President in 2015. Cheng was appointed Chief Medical Officer in March.

  • 30

    Aug

  • 31

    Aug

GILD Gilead
$77.32

0.14 (0.18%)

07/26/18
WELS
07/26/18
NO CHANGE
Target $95
WELS
Outperform
Gilead price target raised to $95 from $89 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Gilead to $95 from $89 following better than expected Q2 operating results. With increasing confidence in 2018 as a trough earnings year, strong HIV growth outpacing HCV decline and emerging data over the next 12 months in large categories of cell therapy, immunology and NASH, the analyst expects continued multiple expansion following Q2 results. He reiterates an Outperform rating on the shares.
07/26/18
07/26/18
DOWNGRADE
Target $79

Neutral
Gilead downgraded to Neutral after CEO resignation at Baird
As previously reported, Baird analyst Brian Skorney downgraded Gilead (GILD) to Neutral from Outperform following the announcement that John Milligan is stepping down as CEO, which he said leaves the company without clear direction. The HIV franchise had an "impressive quarter" and the HCV franchise had "a quarter of stability," but Skorney has concerns over further price erosion after Merck (MRK) just announced a 60% price cut to Zepatier, he tells investors. Yescarta sales, while ahead of his and consensus estimates, were still far from validating the Kite acquisition, added Skorney, who has a $79 price target on Gilead shares.
07/26/18
JEFF
07/26/18
NO CHANGE
Target $95
JEFF
Buy
Gilead stock would be 'trading up nicely' if not for CEO news, says Jefferies
Jefferies analyst Michael Yee said Gilead's Q2 results were solid and consistent with the positive turnaround story that is unfolding and he is confident the stock "would be trading up nicely" if not for the concurrent announcement that "well-liked" John Milligan will be stepping down as CEO. While a CEO search may present a small period of uncertainty, Yee would be a buyer of the stock, which he still sees moving to $90 by year-end amid rising anticipation of Phase 3 NASH data in the first half of next year. Yee keeps a Buy rating and $95 price target on Gilead shares.
08/08/18
HCWC
08/08/18
NO CHANGE
Target $43
HCWC
Buy
Insmed likely to be acquired after positive panel vote, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Insmed (INSM) to $43 from $35 following yesterday's 12-2 FDA panel vote in favor of ALIS in refractory nontuberculous mycobacterial patients. Insmed is now likely to be acquired as ALIS "fits well within the pipeline of a number of larger companies," Fein tells investors in a research note. He expects the company's Q3 conference call "may well be its last." The analyst sees AstraZeneca (AZN), Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) as potential acquirers of Insmed. He reiterates a Buy rating on Insmed.

TODAY'S FREE FLY STORIES

INPX

Inpixon

$3.58

0.04 (1.13%)

08:42
12/10/18
12/10
08:42
12/10/18
08:42
Hot Stocks
Inpixon receives notice of allowance for IPA platform patent from USPTO »

Inpixon announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GCAP

Gain Capital

$7.23

0.03 (0.42%)

08:42
12/10/18
12/10
08:42
12/10/18
08:42
Hot Stocks
GAIN Capital reports November operating metrics »

In the retail segment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRS

Amyris

$4.33

0.16 (3.84%)

08:40
12/10/18
12/10
08:40
12/10/18
08:40
Hot Stocks
Amyris expands production agreement with ADL Bionatur »

Amyris announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFRX

InflaRx

$29.94

0.44 (1.49%)

08:39
12/10/18
12/10
08:39
12/10/18
08:39
Initiation
InflaRx initiated  »

InflaRx initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CLPS

CLPS

$6.30

(0.00%)

08:39
12/10/18
12/10
08:39
12/10/18
08:39
Hot Stocks
CLPS signs MOU with Ngee Ann Polytechnic, Infogain Solutions »

CLPS announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RY

Royal Bank of Canada

$71.07

-0.55 (-0.77%)

08:39
12/10/18
12/10
08:39
12/10/18
08:39
Upgrade
Royal Bank of Canada rating change  »

Royal Bank of Canada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

IDCC

InterDigital

$72.10

-1.93 (-2.61%)

08:38
12/10/18
12/10
08:38
12/10/18
08:38
Hot Stocks
InterDigital announces $100M increase to stock repurchase program »

InterDigital's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GFI

Gold Fields

$3.18

0.065 (2.09%)

08:37
12/10/18
12/10
08:37
12/10/18
08:37
Initiation
Gold Fields initiated  »

Gold Fields initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDI

Standard Diversified

$13.50

(0.00%)

08:37
12/10/18
12/10
08:37
12/10/18
08:37
Hot Stocks
Standard Diversified to acquire Tri-State Consumer Insurance for approx. $54.1M »

Standard Diversified…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUVA

NuVasive

$56.17

-1.68 (-2.90%)

08:37
12/10/18
12/10
08:37
12/10/18
08:37
Hot Stocks
NuVasive gets FDA clearance for expanded use of Monolith Corpectomy System »

NuVasive announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:36
12/10/18
12/10
08:36
12/10/18
08:36
Conference/Events
Raymond James to hold al symposium »

Multi-Family Lending…

BCSF

Bain Capital Specialty Finance

$18.04

-0.13 (-0.72%)

08:36
12/10/18
12/10
08:36
12/10/18
08:36
Initiation
Bain Capital Specialty Finance initiated  »

Bain Capital Specialty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDCC

InterDigital

$72.10

-1.93 (-2.61%)

08:36
12/10/18
12/10
08:36
12/10/18
08:36
Earnings
Breaking Earnings news story on InterDigital »

InterDigital sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CULP

Culp, Inc.

$20.43

-0.3 (-1.45%)

08:35
12/10/18
12/10
08:35
12/10/18
08:35
Hot Stocks
Culp, Inc. announcing passing of chairman, founder Robert Culp, III »

Culp, Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAP

Molson Coors

$63.39

-1.04 (-1.61%)

08:35
12/10/18
12/10
08:35
12/10/18
08:35
Conference/Events
Molson Coors to hold a tour »

Molson Coors HQ &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

MDRX

Allscripts

$9.49

-0.01 (-0.11%)

08:35
12/10/18
12/10
08:35
12/10/18
08:35
Hot Stocks
Allscripts to sell interests in Netsmart for after-tax proceeds of $3 per share »

Allscripts announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLX

Shell Midstream

08:34
12/10/18
12/10
08:34
12/10/18
08:34
Downgrade
Shell Midstream rating change  »

Shell Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMP

BP Midstream

$16.74

-0.16 (-0.95%)

08:34
12/10/18
12/10
08:34
12/10/18
08:34
Downgrade
BP Midstream rating change  »

BP Midstream downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCS

OncoSec

$0.81

-0.0557 (-6.40%)

08:34
12/10/18
12/10
08:34
12/10/18
08:34
Hot Stocks
OncoSec receives $7M investment from Alpha Holdings at $1.50 per share »

OncoSec Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CERS

Cerus

$5.35

-0.22 (-3.95%)

08:32
12/10/18
12/10
08:32
12/10/18
08:32
Hot Stocks
Cerus announces American Red Cross receives BLA approval for INTERCEPT platelets »

Cerus Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDRX

Allscripts

$9.49

-0.01 (-0.11%)

08:32
12/10/18
12/10
08:32
12/10/18
08:32
Hot Stocks
GI Partners, TA Associates to acquire Allscripts' stake in Netsmart Technologies »

GI Partners together with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDRX

Allscripts

$9.49

-0.01 (-0.11%)

08:31
12/10/18
12/10
08:31
12/10/18
08:31
Hot Stocks
Breaking Hot Stocks news story on Allscripts »

GI Partners, TA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCE/A

Forest City Enterprises Inc

$0.00

(0.00%)

, OVAS

OvaScience

$0.70

-0.0335 (-4.57%)

08:30
12/10/18
12/10
08:30
12/10/18
08:30
Options
One new option listing and three option delistings on December 10th »

New option listings for…

FCE/A

Forest City Enterprises Inc

$0.00

(0.00%)

OVAS

OvaScience

$0.70

-0.0335 (-4.57%)

SONC

Sonic

$43.48

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

XPER

Xperi

$12.80

-0.53 (-3.98%)

08:30
12/10/18
12/10
08:30
12/10/18
08:30
Hot Stocks
Breaking Hot Stocks news story on Xperi »

Xperi Corp trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 06

    Jan

VERI

Veritone

$5.62

-0.09 (-1.58%)

08:28
12/10/18
12/10
08:28
12/10/18
08:28
Hot Stocks
Breaking Hot Stocks news story on Veritone »

Veritone up 45% to $8.16…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.